Independent Medical Education Grants

Takeda is committed to supporting high-quality, unbiased, evidence-based independent medical education for healthcare professionals, teams, patients, payers, and systems designed to:

Improve knowledge, enhance skills, and support behavior change
Close clinical and practice gaps
Improve the quality and delivery of patient care
Enable patients to take an active role in their healthcare

Independent Medical Education is defined as a scientific or educational activity(ies) that is evidence-based, fair-balanced, unbiased, and planned and implemented independently of industry influence.

Below are the areas of interest for independent medical education support by Global Medical Affairs Oncology. If you have questions about an area not listed, please contact: [email protected]

Independent Medical Education (IME) Grant Areas of Interest

Gastrointestinal

Colorectal Cancer (CRC)

Unmet needs for metastatic CRC (mCRC); morbidity/mortality, signs and symptoms, patient characteristics throughout the continuum of disease progression.
Treatment options available for previously treated mCRC; incorporating aspects of differentiation based on mechanism of action, therapeutic class, efficacy and safety.
Importance of quality of life (QoL) and patient reported outcomes measures associated with mCRC and treatments available.
Importance and role of allied healthcare providers’ (HCPs) involvement in the management of adverse events related to mCRC late line treatments.
Importance of joint clinical decision making between HCP and the patient for late-line mCRC; and the importance of individualizing patient care.

Hematology

Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Review the evolving treatment landscape in CML and the importance of appropriate TKI sequencing for optimal outcomes and the importance of appropriate dosing to maximize efficacy and minimize safety concerns.
Discuss the risk BCR::ABL1 mutations present (e.g., T315I) in CML and their impact on treatment resistance, the durability of responses, and survival outcomes.
Emphasize the importance of choosing the appropriate TKI for the patient and their disease, mutation testing following tyrosine kinase inhibitors (TKI) failure, and available data to support patients who have failed multiple TKIs.
Education around adverse event (AE) profiles of available therapeutics in CML, recent data readouts, and AE mitigation efforts to help HCPs make well informed clinical decisions.

Lymphoma

Importance of CD30 biology in lymphoma diagnosis and prognosis.
Value of PET imaging in diagnosis and treatment decisions.
Clinician awareness of new developments and their clinical application.
Best practices for front-line and relapsed/refractory (R/R) Hodgkin lymphoma (HL), T-cell lymphomas, cutaneous T-cell lymphoma (CTCL), and systemic anaplastic large cell lymphoma (sALCL).
Awareness of managing potential side effects, including peripheral neuropathy.
Understanding long and short-term toxicities in HL.
Application of real-world evidence in practice.
Staying updated on emerging lymphoma data.
Integration of novel technologies into clinical practice.
Understanding challenges and opportunities in cell therapies.

Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Review frontline treatments for Ph+ ALL, including the dosing strategies, efficacy and safety profiles of available and emerging agents and combinations.
Discuss the risk that mutations present (e.g., T315I) in Ph+ ALL and their impact on treatment resistance, the durability of responses, and survival outcomes.
Emphasize the importance of 1L therapies that can rapidly achieve complete molecular remission, have the potential to suppress mutations that can develop during 1L treatment, and the potential need for appropriate intrathecal care.
Education around adverse event (AE) profiles of available therapeutics in 1L Ph+ ALL, recent data readouts, and AE mitigation efforts to help HCPs make well informed clinical decisions.

Polycythemia Vera (PV)

Describe the unmet needs in PV, focusing on disease burden, accurate diagnosis, and implications of inconsistent hematocrit (Hct) control, stressing the importance of bone marrow biopsy (BMB).
Educate on the importance of Hct Control <45% and risk of thrombosis.
Educate Community clinicians including MD/APP/PharmD on monitoring of PV patients.
Discuss treatment options for patients and guidelines with PV including low v. high risk, phlebotomy and cytoreductive therapies. Emphasizing the implications of prior thrombotic events (TEs) and cardiovascular events.
Discuss burden of phlebotomy and unmet need to control Hct.
Discuss hydroxyurea (HU) intolerance, resistance, and risk of secondary cancers.
Discuss interferon adverse effects and time to onset of action.
Discuss current treatment landscape adverse event (AE) and risk of secondary cancers.
Discuss investigational treatments for PV.
Educate HCPs on shared decision making with patients.
Describe symptoms of PV patients and symptoms of current therapies used in managing PV patients.
Describe the importance of iron dysregulation in PV and associated symptoms. Including phlebotomy worsening iron deficiency and cytoreductive therapies not mechanistically addressing iron deficiency.
Education with symptoms assessment tools and quality of life (QoL) of PV patients.

Thoracic

Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC)

Increase awareness through RWE to identify unmet needs in first-line ALK+ metastatic NSCLC.
Increase awareness of efficacy and safety profiles.
Educate on suitable TKI treatment strategies and other treatment modalities and options at resistance.
Educate on appropriate therapeutic sequencing strategies, focusing on ALK tyrosine kinase inhibitors (TKIs).
Educate clinicians on the importance of informing patients, caregivers, and multidisciplinary teams on the side effects associated with TKI therapies and provide preventive strategies to reduce or ameliorate toxicities.
Ensure awareness of data regarding quality of life (QoL) during treatment with ALK TKIs.
Educate how to facilitate shared decision-making between patients and HCPs in ALK+ NSCLC.

Independent Medical Education Grants | Takeda Oncology